Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Wagner

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology GroupFlorette K Hazard, Angus M S Toland, Serena Y Tan, et al.
Nature Communications|August 2, 2025
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical modelsDarcy Elizabeth Wagner, Hani N Alsafadi, Nilay Mitash, et al.
The New England Journal of Medicine|December 9, 2024
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenSumit Gupta, Rachel E Rau, John A Kairalla, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology GroupFlorette K Hazard, Angus M S Toland, Serena Y Tan, et al.
Nature Communications|August 2, 2025
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical modelsDarcy Elizabeth Wagner, Hani N Alsafadi, Nilay Mitash, et al.
The New England Journal of Medicine|December 9, 2024
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenSumit Gupta, Rachel E Rau, John A Kairalla, et al.
Pageof 4